<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02047539</url>
  </required_header>
  <id_info>
    <org_study_id>1401013288</org_study_id>
    <nct_id>NCT02047539</nct_id>
  </id_info>
  <brief_title>Randomized Controlled Trial of Aspirin vs Placebo in the Treatment of Pre-psychosis</brief_title>
  <official_title>Randomized Controlled Trial of Aspirin vs Placebo in the Treatment of Patients With the Clinical Risk Syndrome for Psychosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to determine whether aspirin is effective in&#xD;
      alleviating symptoms of the clinical high risk (CHR) syndrome for psychosis. The&#xD;
      investigators further aim to determine whether it may delay or prevent the onset of psychosis&#xD;
      in those currently experiencing CHR symptoms. As secondary measures the investigators aim to&#xD;
      collect laboratory studies of inflammation markers and genetic samples to determine whether&#xD;
      certain genetic profiles correlate with risk for psychosis, or response to aspirin treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be randomly assigned to either active treatment (aspirin) or placebo.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">March 2021</completion_date>
  <primary_completion_date type="Actual">March 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Scale of Prodromal Symptoms (SOPS)</measure>
    <time_frame>2 weeks</time_frame>
    <description>Patients randomized to aspirin will improve significantly more on the SOPS total score than patients randomized to placebo</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Scale of Prodromal Symptoms (SOPS)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Patients randomized to aspirin will improve significantly more on the SOPS total score than patients randomized to placebo</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Scale of Prodromal Symptoms (SOPS)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Patients randomized to aspirin will improve significantly more on the SOPS total score than patients randomized to placebo</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Scale of Prodromal Symptoms (SOPS)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Patients randomized to aspirin will improve significantly more on the SOPS total score than patients randomized to placebo</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Clinical High Risk for Psychosis</condition>
  <arm_group>
    <arm_group_label>1000 mg/day aspirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1000 mg/day aspirin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sugar pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>sugar pill</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>1000 mg/day of aspirin 1000 mg/day of sugar pill</description>
    <arm_group_label>1000 mg/day aspirin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>sugar pill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 19 - 35&#xD;
&#xD;
          -  Must have a SIPS interview&#xD;
&#xD;
          -  CHR subjects must meet at least one of 3 CHR syndromes defined by SIPS&#xD;
&#xD;
          -  Must demonstrate adequate decisional capacity&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Under age of 19&#xD;
&#xD;
          -  Have pre-existing gastrointestinal disease, heart disease&#xD;
&#xD;
          -  Have kidney disease&#xD;
&#xD;
          -  Taking non-steroidal anti-inflammatory medications&#xD;
&#xD;
          -  Hypersensitive to NSAID (non-steroidal anti-inflammatory medications)&#xD;
&#xD;
          -  Have coexisting unstable major medical illness&#xD;
&#xD;
          -  Are pregnant or breastfeeding&#xD;
&#xD;
          -  Consume more than 2 drinks of alcohol per day&#xD;
&#xD;
          -  Have a blood clotting disorder&#xD;
&#xD;
          -  Are taking ACE inhibitors, acetazolamide, anticoagulants, anticonvulsants, beta&#xD;
             blockers, diuretics, methotrexate, oral hypoglycemic or uricosuric agents&#xD;
&#xD;
          -  Have a history of substance abuse in past three moths or dependence in past 6 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott W Woods, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PRIME Research Clinic</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>January 24, 2014</study_first_submitted>
  <study_first_submitted_qc>January 27, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2014</study_first_posted>
  <last_update_submitted>May 13, 2021</last_update_submitted>
  <last_update_submitted_qc>May 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psychotic Disorders</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

